MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Stent Phóng Thuốc

  • Home
  • Stent Phóng Thuốc
Sirolimus-Eluting Balloons in Coronary In-Stent Restenosis: Comparative Efficacy Against Repeat DES and Balloon Angioplasty
Posted inCardiology news

Sirolimus-Eluting Balloons in Coronary In-Stent Restenosis: Comparative Efficacy Against Repeat DES and Balloon Angioplasty

Posted by By MedXY 07/07/2026
The SELUTION4ISR trial demonstrates that sirolimus-eluting balloons are a safe and effective noninferior alternative to standard care, including repeat drug-eluting stents, for treating coronary in-stent restenosis at 1 year.
Read More
Can a Sirolimus-Eluting Balloon Reduce Stent Use in De Novo Coronary Disease? New Randomized Evidence from SELUTION DeNovo
Posted inCardiology news

Can a Sirolimus-Eluting Balloon Reduce Stent Use in De Novo Coronary Disease? New Randomized Evidence from SELUTION DeNovo

Posted by By MedXY 06/15/2026
A large randomized trial found sirolimus-eluting balloon with provisional stenting noninferior to routine DES at 1 year by intention-to-treat analysis, though repeat revascularization was slightly higher and per-protocol noninferiority was not confirmed.
Read More
Can a Sirolimus-Eluting Balloon Strategy Rival Routine Stenting in De Novo Coronary Lesions? New Randomized Trial Says Maybe
Posted inCardiology news

Can a Sirolimus-Eluting Balloon Strategy Rival Routine Stenting in De Novo Coronary Lesions? New Randomized Trial Says Maybe

Posted by By MedXY 06/15/2026
An SEB plus provisional stenting strategy was noninferior to routine DES at 1 year for target vessel failure, but repeat revascularization was modestly higher and per-protocol noninferiority was not confirmed.
Read More
  • Mapping Liver Cancer’s Hidden Frontiers: NCACC Uncovers Rare cIgG+ Epithelial Cells Driving Tumor Invasion
  • Germline MSH3 and MLH3 Mutations as Tumor Suppressors Elevating Colorectal Cancer Risk via Hypermutation Signature ID4
  • Natural History and Treatment Outcomes in Hemorrhagic Moyamoya Disease: Insights from a Large Chinese Cohort
  • Unraveling Bibrachial Amyotrophy in Spontaneous Spinal CSF Leaks: Clinical Insights and Surgical Outcomes
  • Circulating Metabolites as Emerging Biomarkers for Stroke Risk Prediction: Insights from the BiomarCaRE Project
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top